GIST (Gastrointestinal Stromal Tumor) , Melanoma , Merkel Cell Carcinoma , Osteosarcoma , Sarcoma , Skin Cancer (Nonmelanoma)
Dr. Andrew (Andy) Brohl is a medical oncologist and physician-scientist. His clinical interest is in the care of patients with a diagnosis of sarcoma or a cutaneous (skin) malignancy, including melanoma. Dr. Brohl’s laboratory research focuses on the utilization of genomics and other high-throughput technologies to learn more about rare cancers and for clinically translational applications. Examples of his current projects include genomic analysis of rare cancer subtypes, identification of drug targets from “-omics” datatypes, application of genomics for personalized cancer therapy, and development of non-invasive molecular profiling technology. Additionally, he is a member of the analysis team for the National Institutes of Health’s “The Cancer Genome Atlas” (TCGA) sarcoma project. Dr. Brohl earned his MD degree from the University of Miami, Miller School of Medicine. He completed an Internal Medicine Residency at Georgetown University and a Hematology and Medical Oncology Fellowship at the National Cancer Institute. He joined Moffitt in 2015 from the Icahn School of Medicine at Mount Sinai where he held dual academic appointments in the Department of Genetics and Genomic Science and the Division of Hematology and Medical Oncology. Dr. Brohl has received numerous academic awards including graduation with research distinction and magna cum laude from Duke University. Also while at Duke, he was named to the Tau Beta Pi engineering honor society, was selected as a Pratt Engineering Undergraduate Fellow, and graduated with dual majors in Biomedical Engineering and Mathematics. During medical school, he was recognized for academic and service contributions, including post-Hurricane Katrina volunteer efforts in southern Mississippi, and was named to the Alpha Omega Alpha medical honor society. Dr. Brohl is currently a member of several professional associations, including the American Association for Cancer Research, Connective Tissue Oncology Society, the Society for Immunotherapy of Cancer, and the American Society of Clinical Oncology.
Education & Training
National Cancer Institute - Hematology and Oncology
Georgetown University - Internal Medicine
University of Miami Miller School of Medicine - MD
CLINICAL TRIAL 19495
A Multicenter, Randomized, Double Blinded, Placebo Controlled, Phase 3 trial of Adjuvant Avelumab (anti PDL1 antibody) in Merkel Cell Carcinoma Patients with Clinically Detected Lymph Node Metastases
Intervention: Avelumab (); MSB00100718C (Avelumab); Placebo ()
CLINICAL TRIAL 20040
A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma
Intervention: Pembrolizumab (Keytruda)
CLINICAL TRIAL 20162
Phase 1 Trial of Intralesional Immunotherapy with IFx-Hu2.0 Vaccine in Patients with Advanced Merkel Cell Carcinoma or Cutaneous Squamous Cell Carcinoma
Intervention: IFx-Hu2.0 ()
CLINICAL TRIAL 20347
A phase 2 basket trial of glutaminase inhibitor (BeGIN) CB-839 HCl in patients with NF1 Aberrations, NF1 mutant malignant peripheral nerve sheath tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant tumors
Intervention: CB-839 HCl ()
CLINICAL TRIAL 20254
A Phase 1b/2, Open-Label Study Evaluating the Safety and Efficacy of KRT-232 in Patients with p53 Wild-Type (p53WT) Merkel Cell Carcinoma (MCC) Who Have Failed Anti-PD-1 or Anti-PD-L1 Immunotherapy, or in Combination with Avelumab in MCC Patients who are Anti-PD-1 or Anti-PD-L1 Treatment Naive
Intervention: Avelumab (); KRT-232 (); MSB00100718C (Avelumab)
CLINICAL TRIAL 19480
The Reveal Study: A Phase 1/2, Open-Label, Multicenter, Dose Escalation And Dose Expansion Study Of Nktr-262 In Combination With Bempegaldesleukin (Nktr-214) And In combination With Bempegaldesleukin (Nktr-214) Plus Nivolumab In Patients With Locally Advanced Or Metastatic Solid Tumor Malignancies
Intervention: BMS-936558 (Nivolumab); NKTR-214 (Bempegaldesleukin); NKTR-262 (); Nivolumab (Opdivo)
CLINICAL TRIAL 20773
Neoadjuvant Lenvatinib Plus Pembrolizumab in Resectable Merkel Cell Carcinoma
Intervention: E7080 (Lenvatinib); Lenvatinib (Lenvima); Pembrolizumab (Keytruda)
Martín-Broto J, Lopez Pousa A, Brohl AS, Van Tine BA, Powers B, Stacchiotti S, Blay JY, Hu JS, Oakley GJ, Wang H, Szpurka AM, Levy DE, Mo G, Ceccarelli M, Jones RL. Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma. Mol Cancer Ther. 2021 Jan.20(1):132-141. Pubmedid: 33177152.
Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Brohl AS, Friedlander PA, Daud A, Kluger HM, Reddy SA, Boulmay BC, Riker A, Burgess MA, Hanks BA, Olencki T, Kendra K, Church C, Akaike T, Ramchurren N, Shinohara MM, Salim B, Taube JM, Jensen E, Kalabis M, Fling SP, Homet Moreno B, Sharon E, Cheever MA, Topalian SL. Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma. J Immunother Cancer. 2021 Apr.9(4). Pubmedid: 33879601. Pmcid: PMC8061836.
Bharmal M, Nolte S, Lebbé C, Mortier L, Brohl AS, Fazio N, Grob JJ, Pusceddu S, Hanna GJ, Hassel JC, Kiecker F, Ellers-Lenz B, Bajars M, Güzel G, Nghiem P, Hunger M, Schlichting M, Henry-Szatkowski M, D'Angelo SP. Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab. Future Oncol. 2020 Sep.16(27):2089-2099. Pubmedid: 32938212.
D'Angelo SP, Bhatia S, Brohl AS, Hamid O, Mehnert JM, Terheyden P, Shih KC, Brownell I, Lebbé C, Lewis KD, Linette GP, Milella M, Georges S, Shah P, Ellers-Lenz B, Bajars M, Güzel G, Nghiem PT. Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial. J Immunother Cancer. 2020 May.8(1). Pubmedid: 32414862. Pmcid: PMC7239697.
Rizk VT, Naghavi AO, Brohl AS, Joyce DM, Binitie O, Kim Y, Hanna JP, Swank J, Gonzalez RJ, Reed DR, Druta M. Chemotherapy improves distant control in localized high-grade soft tissue sarcoma of the extremity/trunk. Clin Sarcoma Res. 2020 Jul.10:11. Pubmedid: 32670544. Pmcid: PMC7350709.
Jinesh GG, Napoli M, Ackerman HD, Raulji PM, Montey N, Flores ER, Brohl AS. Regulation of MYO18B mRNA by a network of C19MC miRNA-520G, IFN-γ, CEBPB, p53 and bFGF in hepatocellular carcinoma. Sci Rep. 2020 Jul.10(1):12371. Pubmedid: 32704163. Pmcid: PMC7378193.
Eroglu Z, Eatrides J, Naqvi SMH, Kim Y, Rich J, Babacan NA, Brohl AS, Markowitz J, Sarnaik A, Zager J, Khushalani NI, Sondak VK, Messina J. Neoadjuvant BRAF-targeted therapy in regionally advanced and oligometastatic melanoma. Pigment Cell Melanoma Res. 2020 Jan.33(1):86-95. Pubmedid: 31329344. Pmcid: PMC6928428.
Rybinski B, Wolinsky T, Brohl A, Moerdler S, Reed DR, Ewart M, Weiser D. Multifocal primary neuroblastoma tumor heterogeneity in siblings with co-occurring PHOX2B and NF1 genetic aberrations. Gene Chromosome Canc. 2020 Feb.59(2):119-124. Pubmedid: 31515834.
Moore CE, Monforte H, Teer JK, Zhang Y, Yoder S, Brohl AS, Reed D. TRIM28 congenital predisposition to Wilms' tumor: novel mutations and presentation in a sibling pair. Cold Spring Harb Mol Case Stud. 2020 Aug.6(4). Pubmedid: 32699065. Pmcid: PMC7476416.
Setty BA, Jinesh GG, Arnold M, Pettersson F, Cheng CH, Cen L, Yoder SJ, Teer JK, Flores ER, Reed DR, Brohl AS. The genomic landscape of undifferentiated embryonal sarcoma of the liver is typified by C19MC structural rearrangement and overexpression combined with TP53 mutation or loss. PLoS Genet. 2020 Apr.16(4):e1008642. Pubmedid: 32310940. Pmcid: PMC7192511.
Weinstein B, Henderson-Jackson E, Cruse CW, Brohl AS. PIK3CA-Related Overgrowth Syndrome (PROS) and Angiosarcoma: A Case Report. Eplasty. 2020 Apr.20:ic6. Pubmedid: 32362992. Pmcid: PMC7180201.
Welch D, Kahen E, Fridley B, Brohl AS, Cubitt CL, Reed DR. Small molecule inhibition of lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) alone and in combination in Ewing sarcoma cell lines. PLoS One. 2019 Sep.14(9):e0222228. Pubmedid: 31550266. Pmcid: PMC6759167.
Geller DS, Levine NL, Hoang BH, Yang R, Weiser D, Morris J, Gorlick R, Gill JB, Roth ME, Tingling J, Brohl AS. Genomic Analysis Does Not Support Malignant Transformation of Osteoblastoma to Osteosarcoma. JCO Precis Oncol. 2019 Sep.3. Pubmedid: 32914027. Pmcid: PMC7446473.
Knepper TC, Montesion M, Russell JS, Sokol ES, Frampton GM, Miller VA, Albacker LA, McLeod HL, Eroglu Z, Khushalani NI, Sondak VK, Messina JL, Schell MJ, DeCaprio JA, Tsai KY, Brohl AS. The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor Therapy. Clin Cancer Res. 2019 Oct.25(19):5961-5971. Pubmedid: 31399473. Pmcid: PMC6774882.
Jinesh GG, Brohl AS. The genetic script of metastasis. Biol Rev Camb Philos Soc. 2019 Oct. Pubmedid: 31663259.
Bridge JA, Sumegi J, Druta M, Bui MM, Henderson-Jackson E, Linos K, Baker M, Walko CM, Millis S, Brohl AS. Clinical, pathological, and genomic features of EWSR1-PATZ1 fusion sarcoma. Mod Pathol. 2019 Nov.32(11):1593-1604. Pubmedid: 31189996.
Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Brohl AS, Friedlander PA, Daud A, Kluger HM, Reddy SA, Boulmay BC, Riker AI, Burgess MA, Hanks BA, Olencki T, Margolin K, Lundgren LM, Soni A, Ramchurren N, Church C, Park SY, Shinohara MM, Salim B, Taube JM, Bird SR, Ibrahim N, Fling SP, Homet Moreno B, Sharon E, Cheever MA, Topalian SL. Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy. J Clin Oncol. 2019 Mar.37(9):693-702. Pubmedid: 30726175. Pmcid: PMC6424137.
Rizk VT, Walko CM, Brohl AS. Precision medicine approaches for the management of Ewing sarcoma: current perspectives. Pharmgenomics Pers Med. 2019 Jan.12:9-14. Pubmedid: 30697061. Pmcid: PMC6340366.
D'Angelo SP, Hunger M, Brohl AS, Nghiem P, Bhatia S, Hamid O, Mehnert JM, Terheyden P, Shih KC, Brownell I, Lebbé C, Lewis KD, Linette GP, Milella M, Schlichting M, Hennessy MH, Bharmal M. Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma. Cancer Immunol Immun. 2019 Apr.68(4):609-618. Pubmedid: 30721341. Pmcid: PMC6447510.
Hicks JK, Henderson-Jackson E, Duggan J, Joyce DM, Brohl AS. Identification of a novel MTAP-RAF1 fusion in a soft tissue sarcoma. Diagn Pathol. 2018 Oct.13(1):77. Pubmedid: 30314519. Pmcid: PMC6186031.
Jinesh GG, Flores ER, Brohl AS. Chromosome 19 miRNA cluster and CEBPB expression specifically mark and potentially drive triple negative breast cancers. PLoS One. 2018 Oct.13(10):e0206008. Pubmedid: 30335837. Pmcid: PMC6193703.
Eroglu Z, Chen YA, Gibney GT, Weber JS, Kudchadkar RR, Khushalani NI, Markowitz J, Brohl AS, Tetteh LF, Ramadan H, Arnone G, Li J, Zhao X, Sharma R, Darville LNF, Fang B, Smalley I, Messina JL, Koomen JM, Sondak VK, Smalley KSM. Combined BRAF and HSP90 Inhibition in Patients with Unresectable BRAFV600E-Mutant Melanoma. Clin Cancer Res. 2018 Nov.24(22):5516-5524. Pubmedid: 29674508. Pmcid: PMC6195480.
Mullinax JE, Hall M, Prabhakaran S, Weber J, Khushalani N, Eroglu Z, Brohl AS, Markowitz J, Royster E, Richards A, Stark V, Zager JS, Kelley L, Cox C, Sondak VK, Mulé JJ, Pilon-Thomas S, Sarnaik AA. Combination of Ipilimumab and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma. Front Oncol. 2018 Mar.8:44. Pubmedid: 29552542. Pmcid: PMC5840208.
Saller J, Walko CM, Millis SZ, Henderson-Jackson E, Makanji R, Brohl AS. Response to Checkpoint Inhibitor Therapy in Advanced Classic Kaposi Sarcoma: A Case Report and Immunogenomic Study. J Natl Compr Canc Ne. 2018 Jul.16(7):797-800. Pubmedid: 30006421.
Pollack MH, Betof A, Dearden H, Rapazzo K, Valentine I, Brohl AS, Ancell KK, Long GV, Menzies AM, Eroglu Z, Johnson DB, Shoushtari AN. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Ann Oncol. 2018 Jan.29(1):250-255. Pubmedid: 29045547. Pmcid: PMC5834131.
Borinstein SC, Steppan D, Hayashi M, Loeb DM, Isakoff MS, Binitie O, Brohl AS, Bridge JA, Stavas M, Shinohara ET, Meyer WH, Reed DR, Wagner LM. Consensus and controversies regarding the treatment of rhabdomyosarcoma. Pediatr Blood Cancer. 2018 Feb.65(2). Pubmedid: 28905489.
Castillo B, Gibbs J, Brohl AS, Seminario-Vidal L. Checkpoint inhibitor-associated cutaneous small vessel vasculitis. JAAD Case Rep. 2018 Aug.4(7):675-677. Pubmedid: 30112452. Pmcid: PMC6092526.
Kahen EJ, Brohl A, Yu D, Welch D, Cubitt CL, Lee JK, Chen Y, Yoder SJ, Teer JK, Zhang YO, Wallace MR, Reed DR. Neurofibromin level directs RAS pathway signaling and mediates sensitivity to targeted agents in malignant peripheral nerve sheath tumors. Oncotarget. 2018 Apr.9(32):22571-22585. Pubmedid: 29854299. Pmcid: PMC5978249.
Brohl AS, Kahen E, Yoder SJ, Teer JK, Reed DR. The genomic landscape of malignant peripheral nerve sheath tumors: diverse drivers of Ras pathway activation. Sci Rep. 2017 Nov.7(1):14992. Pubmedid: 29118384. Pmcid: PMC5678116.
Cancer Genome Atlas Research Network, Brohl AS. Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. Cell. 2017 Nov.171(4):950-965.e28. Pubmedid: 29100075. Pmcid: PMC5693358.
Reed DR, Hayashi M, Wagner L, Binitie O, Steppan DA, Brohl AS, Shinohara ET, Bridge JA, Loeb DM, Borinstein SC, Isakoff MS. Treatment pathway of bone sarcoma in children, adolescents, and young adults. Cancer. 2017 Jun.123(12):2206-2218. Pubmedid: 28323337. Pmcid: PMC5485018.
Brohl AS, Patidar R, Turner CE, Wen X, Song YK, Wei JS, Calzone KA, Khan J. Frequent inactivating germline mutations in DNA repair genes in patients with Ewing sarcoma. Genet Med. 2017 Aug.19(8):955-958. Pubmedid: 28125078. Pmcid: PMC5529247.
Hoggard TM, Henderson-Jackson E, Bui MM, Caracciolo J, Teer JK, Yoder S, Binitie O, Gonzalez RJ, Brohl AS, Reed DR. Myoepithelial carcinoma with RB1 mutation: remarkable chemosensitivity to carcinoma of unknown origin therapy. BMC Cancer. 2017 Apr.17(1):250. Pubmedid: 28390395. Pmcid: PMC5385017.
Kothari N, Teer JK, Abbott AM, Srikumar T, Zhang Y, Yoder SJ, Brohl AS, Kim RD, Reed DR, Shibata D. Increased incidence of FBXW7 and POLE proofreading domain mutations in young adult colorectal cancers. Cancer. 2016 Sep.122(18):2828-2835. Pubmedid: 27244218. Pmcid: PMC5014625.
Ballinger ML, Goode DL, Ray-Coquard I, James PA, Mitchell G, Niedermayr E, Puri A, Schiffman JD, Dite GS, Cipponi A, Maki RG, Brohl AS, Myklebost O, Stratford EW, Lorenz S, Ahn SM, Ahn JH, Kim JE, Shanley S, Beshay V, Randall RL, Judson I, Seddon B, Campbell IG, Young MA, Sarin R, Blay JY, O'Donoghue SI, Thomas DM. Monogenic and polygenic determinants of sarcoma risk: an international genetic study. Lancet Oncol. 2016 Sep.17(9):1261-1271. Pubmedid: 27498913.
Uzilov AV, Ding W, Fink MY, Antipin Y, Brohl AS, Davis C, Lau CY, Pandya C, Shah H, Kasai Y, Powell J, Micchelli M, Castellanos R, Zhang Z, Linderman M, Kinoshita Y, Zweig M, Raustad K, Cheung K, Castillo D, Wooten M, Bourzgui I, Newman LC, Deikus G, Mathew B, Zhu J, Glicksberg BS, Moe AS, Liao J, Edelmann L, Dudley JT, Maki RG, Kasarskis A, Holcombe RF, Mahajan M, Hao K, Reva B, Longtine J, Starcevic D, Sebra R, Donovan MJ, Li S, Schadt EE, Chen R. Development and clinical application of an integrative genomic approach to personalized cancer therapy. Genome Med. 2016 Jun.8(1):62. Pubmedid: 27245685. Pmcid: PMC4888213.
Brohl AS, Khushalani NI, Eroglu Z, Markowitz J, Thapa R, Chen YA, Kudchadkar R, Weber JS. A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma. J Immunother Cancer. 2016 Dec.4:85. Pubmedid: 28031816. Pmcid: PMC5170897.
Chang W, Brohl A, Patidar R, Sindiri S, Shern JF, Wei JS, Song YK, Yohe ME, Gryder BE, Zhang S, Calzone KA, Shivaprasad N, Wen X, Badgett T, Miettinen M, Hartman KR, League-Pascual JC, Trahair T, Widemann BC, Merchant MS, Kaplan RN, Lin JC, Khan J. MultiDimensional ClinOmics for Precision Therapy of Children and Adolescent Young Adults with Relapsed and Refractory Cancer: A Report from the Center for Cancer Research. Clin Cancer Res. 2016 Aug.22(15):3810-3820. Pubmedid: 26994145. Pmcid: PMC4970946.
Brohl AS, Demicco EG, Mourtzikos K, Maki RG. Response to sunitinib of a gastrointestinal stromal tumor with a rare exon 12 PDGFRA mutation. Clin Sarcoma Res. 2015 Sep.5:21. Pubmedid: 26396737. Pmcid: PMC4578851.
Brock CO, Brohl AS, Običan SG. Incidence, pathophysiology, and clinical manifestations of antiphospholipid syndrome. Birth Defects Res C Embryo Today. 2015 Sep.105(3):201-208. Pubmedid: 26396056.
Brohl AS, Stinson JR, Su HC, Badgett T, Jennings CD, Sukumar G, Sindiri S, Wang W, Kardava L, Moir S, Dalgard CL, Moscow JA, Khan J, Snow AL. Germline CARD11 Mutation in a Patient with Severe Congenital B Cell Lymphocytosis. J Clin Immunol. 2015 Jan.35(1):32-46. Pubmedid: 25352053. Pmcid: PMC4466218.
Brohl AS, Li L, Andikyan V, Običan SG, Cioffi A, Hao K, Dudley JT, Ascher-Walsh C, Kasarskis A, Maki RG. Age-stratified risk of unexpected uterine sarcoma following surgery for presumed benign leiomyoma. Oncologist. 2015 Apr.20(4):433-439. Pubmedid: 25765878. Pmcid: PMC4391766.
Brohl AS, Solomon DA, Chang W, Wang J, Song Y, Sindiri S, Patidar R, Hurd L, Chen L, Shern JF, Liao H, Wen X, Gerard J, Kim JS, Lopez Guerrero JA, Machado I, Wai DH, Picci P, Triche T, Horvai AE, Miettinen M, Wei JS, Catchpool D, Llombart-Bosch A, Waldman T, Khan J. The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation. PLoS Genet. 2014 Jul.10(7):e1004475. Pubmedid: 25010205. Pmcid: PMC4091782.
Shern JF, Chen L, Chmielecki J, Wei JS, Patidar R, Rosenberg M, Ambrogio L, Auclair D, Wang J, Song YK, Tolman C, Hurd L, Liao H, Zhang S, Bogen D, Brohl AS, Sindiri S, Catchpoole D, Badgett T, Getz G, Mora J, Anderson JR, Skapek SX, Barr FG, Meyerson M, Hawkins DS, Khan J. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. Cancer Discov. 2014 Feb.4(2):216-231. Pubmedid: 24436047. Pmcid: PMC4462130.
Solomon DA, Brohl AS, Khan J, Miettinen M. Clinicopathologic features of a second patient with Ewing-like sarcoma harboring CIC-FOXO4 gene fusion. Am J Surg Pathol. 2014 Dec.38(12):1724-1725. Pubmedid: 25321332. Pmcid: PMC4229425.
Farid M, Ahn L, Brohl A, Cioffi A, Maki RG. Consumptive coagulopathy in angiosarcoma: a recurrent phenomenon?. Sarcoma. 2014 Apr.2014:617102. Pubmedid: 24693222. Pmcid: PMC3945465.
Brohl AS, Song JY, Lieberman R, Gause B. Synchronous indolent primary gastrointestinal lymphomas managed successfully with conservative measures. Am J Ther. 20(5):549-553. Pubmedid: 22020085. Pmcid: PMC3266981.
Snyder M, Gangadhara S, Brohl AS, Ludlow S, Nanjappa S. Serotonin Syndrome Complicating Treatment of Ifosfamide Neurotoxicity With Methylene Blue. Cancer Control. 24(5):1073274817729070. Pubmedid: 28975823. Pmcid: PMC5937239.
The Provider Rating is an average of all responses to specific care provider-related
questions from our nationally-recognized
Press Ganey Patient Satisfaction Survey.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Patients that are treated in outpatient or hospital environments may receive
different surveys, and the volume of responses will vary by question.
Comments are gathered from specific care provider-related questions from our
Patient Satisfaction Survey . The comments are submitted by patients
and reflect their views and opinions. Patients are de-identified for confidentiality and
We post both positive and negative comments from the surveys. We do not post comments
that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may
risk the privacy of our patients.
A “[…]” in the comments below indicates de-identified patient information or comments that
are unrelated to the patient’s experience with the visit to the provider, such as
comments related to another provider, about the survey itself, or otherwise completely
Not all providers will have a star rating or comments. In order to ensure accuracy of our
ratings, we only display ratings for providers who have a minimum of 30 completed from
the previous 12 months.
Provider Ratings and comments are gathered from our nationally-recognized Press Ganey
Patient Satisfaction Survey. If a provider does not have ratings or comments listed it
can be for several reasons, including:
The provider has not yet received the minimum number of patient satisfaction surveys
to be eligible for display. We require a minimum of 30 surveys before we post
results to ensure that the rating is statistically reliable and a true reflection of
He or she may be a researcher or other type of provider that does not see patients.
The provider practices in a specialty or office that does not use the specified
surveys currently used for these ratings.
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate buttonbelow. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.
Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub